ÀÏÀß·¯Ã¤¿ë°ü
ä¿ëÁ¤º¸
ÀÎÀç°Ë»ö
±³À°Á¤º¸
ÇìµåÇåÆÃ
½º¸¶Æ®Å¸¿î
ȸ¿ø¼­ºñ½º
À̷¼­ µî·Ï
ä¿ë°ø°í µî·Ï

Medical Science Liaison Xarelto

¾÷Á¾ ÀÇ·á/Á¦¾à/°Ç°­ ÀÚº»±Ý
±â¾÷ÇüÅ ¿Ü±¹±â¾÷ ¸ÅÃâÇöȲ
´ëÇ¥ÀÚ »ç¿ø¼ö
ȸ»çÁÖ¼Ò ¼­¿ïƯº°½Ã µ¿ÀÛ±¸ º¸¶ó¸Å·Î5±æ 23 (½Å´ë¹æµ¿ 395-62) »ï¼ºº¸¶ó¸Å ¿È´ÏŸ¿ö
  • ÇöÀç ä¿ëÁ¤º¸¸¦ º¹»çÇÕ´Ï´Ù.
  • ÇöÀç ä¿ëÁ¤º¸¸¦ ÇÁ¸°ÆÃÇÕ´Ï´Ù.




Á÷Á¾ º¸°Ç¡¤ÀÇ·á
±Ù¹«ÇüÅ Á¤±ÔÁ÷ ä¿ëÁ÷±Þ -
¸ðÁýÀοø 0 ¸í ³ªÀÌ Á¦ÇѾøÀ½
°æ·Â °æ·Â ±Þ¿©Á¶°Ç ´ç»ç±ÔÁ¤
Çз ´ëÁ¹ ÀÌ»ó Á¢¼ö±â°£ Á¢¼ö±â°£ÀÌ Áö³µ½À´Ï´Ù
 [ȨÆäÀÌÁöÁ¢¼ö]

Á¢¼ö±â°£ÀÌ Áö³µ½À´Ï´Ù

* ´ã´ç¾÷¹«
»ó¼¼Á¶°Ç

Medical Science Liaison Xarelto

¸ðÁýºÎ¹® ¹× ÀÚ°Ý¿ä°Ç













¸ðÁýºÎ¹®



´ã´ç¾÷¹«



ÀÚ°Ý¿ä°Ç



Medical Science Liaison Xarelto



1.
Exchange and dissemination of scientific, educational, and research related
information: The MSL plans, partners and engages with TLs as a subject matter
expert and colleague both proactively and reactively via various innovative
TL engagements tactics and formats to provide dissemination, clarification
and education of scientific data, study protocols, meeting abstracts, and
professional literature (Both proactive discussions on-label, and reactive
discussions for unsolicited off-label questions in alignment with local
regulations).


2.
TL Identification / profiling / segmentation and strategy and engagement
planning: In alignment with medical strategy as stipulated in the integrated
brand plan, the MSL contributes to internal understanding of specific TL
interests, expertise and impact in the medical community at large.


3.
Participation at / networking in Congresses and Conventions: The MSL uses
congresses and conventions to network with TLs, establish new contacts, and gather
competitive intelligence.


4.
Coordination of Scientific Education Activities and Advisory Boards: The MSL
plans and organizes scientific training, education events / sessions and
advisory boards with TLs within their specific therapeutic area.


5.
Preparing reports and tracking activities: The MSL submits timely reports of
field interactions and events, as well as tracks activities against agreed
upon PMP objectives and country medical activity plan.


6.
Collecting Investigator Initiated Research (IIR) ideas and facilitating IIR
set-up: The MSL acts as a point of contact for investigators, facilitating
the interface with investigators and appropriate Pharma personnel responsible
for approval, and communication of study progress and completion


7.
Interactions with Medical Societies: The MSL answers medical / scientific
queries of Medical Societies with regards to Pharma products.



-
Bachelor¡¯s degree in natural sciences, pharmacology or medicine. Advanced
degree in science-related field eg. MD, PharmD, PhD preferred.


-
2 years of experience in the pharmaceutical industry as an MSL preferred or
experience in drug information, clinical research and development, or other
clinical relevant activities.


-
Academic / scientific writing experience either through educational
background and / or job experience


-
Basic knowledge of therapeutic area products


-
Participated in a project from inception to conclusion


-
Excellent presentation and written and verbal communication skills


-
Understanding of clinical trial design and rationale


-
Ability to work in a team environment


-
Ability to build productive work-relationships both internally and externally


-
Ability to work independently and a demonstrated self-starter


-
Basic problem-solving skills


-
Good organization skills with thorough attention to detail ensuring timely
follow-through and closure with Thought Leaders and fellow MSL


-
Strives to impact individuals and organisations


-
Exhibits interpersonal awareness


-
Demonstrated business acumen


-
Strong statistical skills and ability to extract insights from data preferred


Á¢¼ö¹æ¹ý

  • - ´ç»ç ȨÆäÀÌÁö¸¦ ÅëÇÑ ¿Â¶óÀÎ ÀÔ»çÁö¿ø

Á¢¼ö±â°£

  • - 2016.08.09 ~ 2016.08.22±îÁö




* ÀÔ»çÁö¿ø ½Ã Áß¿ä»çÇ×À» ²À üũÇϼ¼¿ä!

* ±Ù¹«È¯°æ
±Ù¹«Áö¿ª : ¼­¿ï
±Þ¿©Á¶°Ç : ´ç»ç±ÔÁ¤
* Á¢¼ö°³¿ä

¿À´Ã¸¶°¨

Á¢¼ö±â°£ÀÌ Áö³µ½À´Ï´Ù

¡á Á¢¼ö±â°£   ¡á ¿À´Ã   ¡á ¸¶°¨

2016. 08

  • ÀÏ
  • ¿ù
  • È­
  • ¼ö
  • ¸ñ
  • ±Ý
  • Åä
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
* ´ã´çÀÚ Á¤º¸
¸ðÁý±â°£ÀÌ Áö³­ ä¿ëÁ¤º¸ÀÇ °æ¿ì ´ã´çÁ¤º¸´Â °ø°³µÇÁö ¾Ê½À´Ï´Ù.
ÇöÀç ä¿ëÁ¤º¸¸¦ º¹»çÇÕ´Ï´Ù. ÇöÀç ä¿ëÁ¤º¸¸¦ ÇÁ¸°ÆÃÇÕ´Ï´Ù.

µî·Ï : 2016³â 8¿ù 16ÀÏ (È­) 22:35    ÃÖÁ¾¼öÁ¤ : 2016³â 8¿ù 17ÀÏ (¼ö) 06:57

º» Á¤º¸´Â ¹ÙÀÌ¿¤ÄÚ¸®¾Æ ¿¡¼­ Á¦°øÇÑ ÀÚ·áÀ̸ç, ½ºÄ«¿ìÆ®Àº(´Â) ±× ³»¿ë»óÀÇ ¿À·ù ¹× Áö¿¬, ±× ³»¿ëÀ» ½Å·ÚÇÏ¿© ÃëÇØÁø Á¶Ä¡¿¡ ´ëÇÏ¿© Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. º» Á¤º¸´Â ½ºÄ«¿ìÆ®ÀÇ µ¿ÀÇ ¾øÀÌ Àç¹èÆ÷ÇÒ ¼ö ¾ø½À´Ï´Ù.

¢À ½ºÄ«¿ìÆ® ¿¡¼­´Â °ÅÁþ ±¸ÀÎ ±¤°í¿¡ ´ëÇÑ ÇÇÇØ¸¦ ÃÖ¼ÒÈ­ Çϱâ À§ÇÏ¿© ÇãÀ§ ä¿ë°ø°í¿¡ ½Å°íÁ¦µµ¸¦ ½ÃÇàÇϰí ÀÖ½À´Ï´Ù.
°ÅÁþ±¸Àα¤°í¿¡ ´ëÇÑ ±¸Á÷ÀÚÁÖÀÇ»çÇ× ½Å°íÆ÷»ó±ÝÁ¦ ¾È³» ÇãÀ§ ä¿ë°ø°í ½Å°íÇϱâ

±Ù¹«Áö À§Ä¡ º¸±â

±Ù¹«Áö ÁÖ¼Ò

¼­¿ïƯº°½Ã µ¿ÀÛ±¸ º¸¶ó¸Å·Î5±æ 23 (½Å´ë¹æµ¿ 395-62) »ï¼ºº¸¶ó¸Å ¿È´ÏŸ¿ö

Å©°Ôº¸±â

[ƯÁý±âȹ] ¹ý·ü»ç¹«Á÷

Á÷¾÷µ¸º¸±â

¹ý·ü»ç¹«Á÷À̶õ?º¯..

¸éÁ¢ helper

¸éÁ¢Áú¹®

Àμº ¡Ú¡Ú¡Ú¡Ú
Àû¼º ¡Ú¡Ú¡Ú¡Ú

Special Interview

½ºÆä¼ÈÀÎÅͺä
¹ý·ü »ç¹«Á÷À̶ó´Â ÀÏÀÌ ¾î¶² ÀÏÀÎÁö Àß ¸ð..

À¯»çÁ÷Á¾ÀÇ Ã¤¿ë Á¤º¸